drugset / Trial / NCT05725200
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.
Timeline
- Start
- 2022-09-27
- Primary completion
- 2038-12-31
- Completion
- 2040-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alectinib | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Crizotinib | Small molecule | — | — |
| Subject | Encorafenib | Small molecule | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Idelalisib | Small molecule | — | — |
| Subject | Larotrectinib | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Palbociclib | Small molecule | — | — |
| Subject | Panobinostat | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Petrozumab | Unknown | — | — |
| Subject | Talazoparib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Subject | Venetoclax | Small molecule | — | — |
| Subject | dasatinib anhydrous | Small molecule | — | — |